- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03611868
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.
Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Part 1 is the open label, dose-escalation phase Ib portion of the study to establish the maximum tolerated dose (MTD)/RP2D of APG-115 in combination with pembrolizumab. APG-115 will be administered orally every other day (QOD) for consecutive 2 weeks and 1 week off dosing as a cycle of 21 days (3 weeks), pembrolizumab will administrated with label dose.
Part 2 is a phase II study design. The patients will be treated with APG-115 at 150 mg QOD (RP2D) in combination with pembrolizumab until disease progression, unacceptable toxicity, or another discontinuation criterion is met. Part 2 includes patients with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) refractory/relapsed melanoma and MPNST.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Angela Kaiser
- Phone Number: 301-509-0357
- Email: Angela.Kaiser@ascentage.com
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia
- Recruiting
- Metro South Hospital and Health Services via Princess Alexandra Hospital
-
Contact:
- Steve Turner
- Phone Number: +61 7 3443 7288
- Email: trials@tri.edu.au
-
Principal Investigator:
- Kenneth O'Byrne
-
South Brisbane, Queensland, Australia, 4101
- Recruiting
- Queensland Children's Hospital
-
Contact:
- Steve Foresto
- Phone Number: +61 7 3068 1111
-
Principal Investigator:
- Steven Foresto
-
-
South Australia
-
Bedford Park, South Australia, Australia, 5042
- Recruiting
- Flinders Medical Centre
-
Principal Investigator:
- Christos Karapetis
-
Contact:
- Alison Richards
- Phone Number: 82046200
- Email: Alison.richards@sa.gov.au
-
-
Victoria
-
Heidelberg, Victoria, Australia
- Recruiting
- Austin Health
-
Contact:
- Anne-Marie Woods
- Phone Number: 03 9496 3088
- Email: anne-marie.woods@austin.org.au
-
Principal Investigator:
- Damien Kee
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- Recruiting
- University of Arizona Cancer Center
-
Contact:
- Montaser Shaheen
- Phone Number: 520-626-5972
- Email: shaheenm@email.arizona.edu
-
Principal Investigator:
- Montaser Shaheen, MD
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Recruiting
- Highlands Oncology
-
Contact:
- Allie Pittman, MD
- Phone Number: 479-695-4167
- Email: apittman@hogonc.com
-
Principal Investigator:
- Thad Beck, MD
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Hematology & Oncology Clinic
-
Contact:
- Rosleen Mala
- Phone Number: 310-794-3879
- Email: RMala@mednet.ucla.edu
-
Principal Investigator:
- Bartosz Chmielowski, MD
-
Santa Monica, California, United States, 90403
- Not yet recruiting
- Sarcoma Oncology Research Center
-
Principal Investigator:
- Sant P Chawla, MD
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Recruiting
- Children's National Research Institute
-
Contact:
- Shari Walker
- Phone Number: 202-476-2802
- Email: dvl@childrensnational.org
-
Principal Investigator:
- AeRang Kim, MD, PhD
-
-
Florida
-
Fort Myers, Florida, United States, 33908
- Recruiting
- Sarah Cannon/FCSRI
-
Contact:
- Joseph Morris
- Phone Number: 845-661-4479
- Email: Joseph.Morris@FLCancer.com
-
Principal Investigator:
- James Reeves, MD
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- Washington University School of Medicine
-
Contact:
- Michele Landeau
- Phone Number: 314-747-9488
- Email: landeaum@wustl.edu
-
Principal Investigator:
- Brian Van Tine, MD, PhD
-
-
New York
-
New York, New York, United States, 10065
- Recruiting
- Memorial Sloan Kettering
-
Contact:
- Sujana Movva
- Email: zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org
-
Principal Investigator:
- Sujana Movva, MD
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke Cancer Institute
-
Principal Investigator:
- April Salama, MD
-
Contact:
- Carol Ann Wiggs
- Phone Number: 919-684-0281
- Email: carolann.wiggs@duke.edu
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Principal Investigator:
- Brian Gastman, MD
-
Contact:
- Phone Number: 866-223-8100
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Recruiting
- Penn State Hershey Medical Center Cancer Institute
-
Principal Investigator:
- Joseph Drabick, MD
-
Contact:
- Barbara Husic
- Phone Number: 717-531-5471
- Email: bhusic@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Principal Investigator:
- Marlana Orloff, MD
-
Contact:
- Carolyn Palumbo
- Phone Number: 215-955-9980
- Email: carolyn.palumbo@jefferson.edu
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon Cancer Center
-
Principal Investigator:
- Meredith McKean, MD
-
Contact:
- Phone Number: 844-482-4812
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- University of Texas MD Anderson Cancer Center
-
Contact:
- Gracy Zacharian
- Email: gzachari@mdanderson.org
-
Principal Investigator:
- Neeta Somaiah, MD
-
San Antonio, Texas, United States, 78229
- Recruiting
- NEXT Oncology
-
Contact:
- Anthony Tolcher
- Phone Number: 210-580-9500
- Email: atolcher@nextoncology.com
-
Principal Investigator:
- Anthony Tolcher, MD
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Recruiting
- Virginia Cancer Specialists
-
Contact:
- Carrie Friedman
- Email: Carrie.Friedman@usoncology.com
-
Principal Investigator:
- Alexander Spira, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or non-pregnant, non-lactating female patients age ≥18 years, an exception for MPNST cohort: adolescents ≥12 years old (who weigh at least 40 kg) is allowed
Part 2:
- Measurable disease according to RECIST 1.1. Lesions situated in a previously irradiated area, or an area subject to other loco-regional therapy (e.g., intralesional injections) should be considered non-measurable
- ECOG performance status 0-2
- Cohort A: Histologically confirmed, unresectable or metastatic melanoma, and refractory or relapse after PD-1 antibody treatment and ineligible for other standard of care therapy per NCCN guideline (previous PD-1/PD-L1 antibody treatment not required for uveal melanoma)
- Cohort F: Histologically confirmed, metastatic or unresectable MPNST
- Life expectancy ≥ 3 months
- Continuance of treatment related toxicities (except alopecia) due to prior radiotherapy or chemotherapy agents or biological therapy (including PD-1/PD-L1 antibodies) must be ≤ grade 1 at the time of dosing
- Adequate bone marrow and organ function as indicated by the following laboratory values without continuous supportive treatment (such as blood transfusion, coagulation factors and/or platelet infusion, red/white blood cell growth factor administration, or albumin infusion) as assessed by laboratory for eligibility
- QTcF interval (mean of 3, 1-3 minutes between tests) ≤450 ms in males and ≤470 ms in females
- Left ventricular ejection fraction (LVEF) ≥ lower limit of institutional normal (LLN) as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan
- Tumor tissue must be provided for all subjects for biomarker analysis before treatment with investigational product
- Willingness to use contraception by a method that is deemed effective by the investigator by both male and female patients of child bearing potential (postmenopausal women must have been amenorrhea for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug
- Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any screening procedures). Willingness and ability to comply with study procedures and follow-up examination.
Exclusion Criteria:
- Any prior systemic MDM2-p53 inhibitor treatment
- Received chemotherapy within 21 days (42 days for nitrosoureas or mitomycin C) prior to first dose
- Part 2 Cohort A: Prior loco-regional treatment with intralesional therapy (e.g., talimogene laherparepvec) for unresectable or metastatic melanoma in the last 6 weeks prior to start of study treatment
- Part 2 Cohort B: Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of trial treatment
- Part 2 Cohort E: Known FGFR translocation mutation
- Received hormonal and biologic, small molecule targeted therapies or other anti-cancer therapy within 21 days prior to first dose
- Radiation or surgery within 14 days prior to first dose, thoracic radiation within 28 days prior to first dose
- Has known active central nervous (CNS) metastases and/or carcinomatous meningitis. Or has neurologic instability per clinical evaluation due to tumor involvement of the CNS.
- Requirement for corticosteroid treatment (with the exception of megestrol and local use of steroid: i.e., topical corticosteroids, inhaled corticosteroids for reactive airway disease, ophthalmic, intraarticular, and intranasal steroids
- Concurrent treatment with an investigational agent or device within 21 days prior to the first dose of therapy
- Failure to recover adequately, as judged by the investigator, from prior surgical procedures. Patients with active wound healing, patients who have had major surgery within 28 days from 1st dose of study treatment, and patients who have had minor surgery within 14 days from 1st dose of study treatment.
- Unstable angina, myocardial infarction, or a coronary revascularization procedure within 180 days of study entry
- Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation
- Active infection requiring systemic antibiotic/ antifungal medication, and known clinically active viral infection such as hepatitis B or C, HIV infection, or active COVID-19
- Uncontrolled concurrent illness including, but not limited to: symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements
- Has an active autoimmune disease, or a documented history of autoimmune disease, or a syndrome, that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections are not excluded from the study. Subjects with hypothyroidism stable on hormone replacement are not excluded from the study.
- Has received a live vaccine within 30 days prior to first dose. Note that killed vaccines, mRNA vaccines, and non-live attenuated vaccines (i.e., for the SARS-Cov-2 virus or COVID-19) are allowed for patients on study.
- Has had an allogeneic tissue/solid organ transplant, prior stem cell or bone marrow transplant
- Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Has previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
- Any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study
- History of organ transplant requiring use of immunosuppressive medication
- A woman of childbearing potential who has a positive urine or serum pregnancy test (within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: APG-115+Pembrolizumab open label, two-part phase Ib/II
single arm dose escalation and dose expansion
|
dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200 mg.
APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie.
dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3-weeks a cycle.
Pembrolizumab is administrated following FDA approved label dose, i.e., 200 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose
Time Frame: 21 days
|
Part I is to assess the safety and tolerability of APG-115 by assessing the dose-limiting toxicity (DLT) of APG-115 in combination with pembrolizumab.
End points included: Incidence of DLTs during the first 3 weeks of treatment of each dose cohort; Severity and frequency of any adverse event(s) (AE) and serious adverse event(s) (SAE) based on NCI CTCAE 5.0
|
21 days
|
Recommended Phase II Dose
Time Frame: 21 days
|
Part I is aimed to generate data to select the recommended Phase II dose
|
21 days
|
Overall Response Rate
Time Frame: up to 12 months
|
Phase II is to assess overall response rate of APG-115 in combination with pembrolizumab defined as the percentage of subjects with a best overall confirmed complete response (CR) or a partial response (PR) at any time as per RECIST 1.1
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Yifan Zhai, MD, PhD, Ascentage Pharma Group Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neuromuscular Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Peripheral Nervous System Diseases
- Nervous System Neoplasms
- Neoplasms, Connective Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Sarcoma
- Peripheral Nervous System Neoplasms
- Neoplasms, Fibrous Tissue
- Fibrosarcoma
- Neurofibroma
- Neoplasms
- Melanoma
- Nerve Sheath Neoplasms
- Neurofibrosarcoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- APG-115-US-002
- Keynote MK-3475-B66 (Other Identifier: Merck and Co.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Viewpoint Molecular TargetingRecruitingMetastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, UvealUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus
Clinical Trials on APG-115+Pembrolizumab
-
Ascentage Pharma Group Inc.RecruitingT-Prolymphocytic LeukemiaUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingSolid Tumor | NeuroblastomaChina
-
Ascentage Pharma Group Inc.CompletedPatients With Advanced Solid Tumor or LymphomaUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingAdvanced Solid Tumor | LiposarcomaChina
-
University of Michigan Rogel Cancer CenterAscentage Pharma Group Inc.SuspendedSalivary Gland Cancer | Malignant Salivary Gland CancerUnited States
-
Ascentage Pharma Group Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | AML | MDS | CMML | High-risk Myelodysplastic SyndromeUnited States
-
Ascentage Pharma Group Inc.CompletedSmall Cell Lung Cancer | Solid TumorUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.RecruitingEsophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma | Advanced Solid CancerChina
-
Gilead SciencesTerminatedNon-Hodgkin's Lymphoma | Chronic Lymphocytic LeukemiaUnited States
-
Ascentage Pharma Group Inc.Suzhou Yasheng Pharmaceutical Co., Ltd.TerminatedSmall Cell Lung Cancer and Other Solid TumorsChina